A study by US Food and Drug Administration (FDA) officials published in JAMA Internal Medicine earlier this week found that competitive generic therapies (CGTs) approved by the US Food and Drug Administration (FDA) were launched faster than traditional generics. This swift launch enables these products to compete more quickly with brand-name drugs, the authors said.
The study authors attributed the faster CGT entry “to the use or lose” nature of CGT exclusivity...[JamaJournalNetwork]
